---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-006304"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-02T00:01:42.540888+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints

## Summary
- Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.
- No revenue in Q3 (Vyleesi rights sold Dec 2023); net loss $8.4M ($0.53 loss per share) vs $8.7M ($0.76) a year ago.
- Cash and equivalents $10.0M as of March 31, 2024; expects to fund operations into 2H calendar 2024; raised $10M in registered direct offering in Jan 2024.
- Obesity: Phase 2 trial of MCR4 agonist + GLP-1 targeted to start Q2 2024 with topline data in 2H 2024.
- Male ED: Phase 2 trial of bremelanotide + PDE5i in non-responders targeted to start Q2 2024, topline expected 2H 2024.

## SEC filing metadata
- accession: 0001654954-24-006304
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/0001654954-24-006304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-006304
- JSON: https://secwatch.observer/filing/0001654954-24-006304.json
- Plain text: https://secwatch.observer/filing/0001654954-24-006304.txt

## Key facts
- Earnings Releases
  PALATIN TECHNOLOGIES INC reported financial results for fiscal third quarter ended March 31, 2024.
  - Period: fiscal third quarter ended March 31, 2024
  - Result: reported results
  source text: On May 15, 2024, we issued a press release including results for our quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/911216/000165495424006304/0001654954-24-006304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.